Feb 22, 2018 by Brian Orelli, PhDWhy Sangamo Therapeutics Rocketed Higher TodayThe gene editing company scores another deal.
Feb 20, 2018 by Brian Orelli, PhDWhy Adamas Pharmaceuticals Fell TodayPotential competition has investors spooked.
Feb 15, 2018 by Brian Orelli, PhDWhy Sorrento Therapeutics Jumped Higher TodayInvestors crowd into the biotech ahead of a potential approval at the end of the month.
Feb 14, 2018 by Brian Orelli, PhDWhy DBV Technologies Jumped Higher TodayThe FDA is "supporting" the biotech submitting a marketing application for Viaskin Peanut, but how strong that support is remains to be seen.
Feb 13, 2018 by Brian Orelli, PhDWhy Karmon's "Positive" Data Turned Into a 21% DeclineSometimes the devil is in the details.
Feb 13, 2018 by Brian Orelli, PhDImmunoGen Moves One Foot ForwardOne step at a time is the only way to complete the marathon of drug development.
Feb 12, 2018 by Brian Orelli, PhDWhy ImmunoGen Jumped Higher TodayInvestors are jumping back into the biotech for no apparent reason.
Feb 12, 2018 by Brian Orelli, PhDAlnylam Pharmaceuticals Starts the Wait for ApprovalFollowing solid data from the Apollo phase 3 trial, an approval of patisiran seems likely.
Feb 9, 2018 by Brian Orelli, PhDNatus Medical Hears a Rebound ComingA revenue miss in the fourth quarter comes from rather mundane issues that appear to be largely behind the medical-supply company.
Feb 8, 2018 by Brian Orelli, PhDSeattle Genetics Is Growing Up Any Way It CanThe biotech looks to build revenue through a label expansion, an acquisition, and developing its internal pipeline.
Feb 7, 2018 by Brian Orelli, PhDWhy Abeona Therapeutics Jumped 14% on WednesdayPositive clinical trial data from a single patient sends shares soaring.
Feb 7, 2018 by Brian Orelli, PhDBecton, Dickinson Ready to Sing a New SongThe addition of Bard will start paying off this year.
Feb 6, 2018 by Brian Orelli, PhDNovo Nordisk's Dichotomy AboundsIt's a tale of two cities for the diabetes specialist.
Feb 5, 2018 by Brian Orelli, PhDWhy ImmunoGen Inc. Pulled Back TodayFor the biotech's non-fundamental moves, what goes up, must come down.
Feb 5, 2018 by Brian Orelli, PhDIDEXX Laboratories Separates From the PackThe animal-testing company is growing faster than its customers.
Feb 2, 2018 by Brian Orelli, PhDQiagen Tops Off 2017 With Solid Earnings and an AcquisitionRestructuring is helping the scientific-test maker to become more efficient.
Feb 1, 2018 by Brian Orelli, PhDVertex Pharmaceuticals Picks Between "Sirloin Steak and Filet Mignon"Solid fourth-quarter earnings get topped off by impressive phase 2 data for the biotech's next-generation cystic fibrosis drugs.
Jan 30, 2018 by Brian Orelli, PhDCelgene Looking Good With Plans for More GrowthThe biotech's partnerships and acquisitions are about to start paying off.
Jan 29, 2018 by Brian Orelli, PhDBiogen Inc. Caps Off a Solid 2017, Waits on AducanumabThis year won't be quite as productive.
Jan 25, 2018 by Brian Orelli, PhDThe Most Likely Reason Why MannKind Corporation Skyrocketed Higher TodayAnother no-news jump for the inhaled insulin expert
